Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

280
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
280
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

264
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
264
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

578
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
578
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

250
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
250
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models00:57

Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models

353
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
353
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

301
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
301

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantifying Transporter Activity: An Absolute Scaling Approach Using Digoxin.

Molecular pharmaceutics·2026
Same author

Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions With the Antibody-Drug Conjugate Trastuzumab Deruxtecan.

CPT: pharmacometrics & systems pharmacology·2026
Same author

How can we overcome the pharmacokinetic challenges posed when conducting complex DDI studies?

Expert opinion on drug metabolism & toxicology·2026
Same author

Stakeholder input towards further refinement and consolidation of the alternative safety profiling algorithm (ASPA) for next generation risk assessment (NGRA).

ALTEX·2026
Same author

Evaluating alterations in drug-metabolizing enzymes in cancer: insights from in vivo, in vitro, and biomarker studies.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

From Global Impact to Pharmacoequity: A Call to Action for Clinical Pharmacology.

Clinical pharmacology and therapeutics·2026

Related Experiment Video

Updated: Feb 12, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.6K

Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach.

Udoamaka Ezuruike1, Helen Humphries1, Maurice Dickins1

  • 1Simcyp Limited (a Certara company), Sheffield, UK.

Clinical Pharmacology and Therapeutics
|April 12, 2018
PubMed
Summary
This summary is machine-generated.

This study developed a pharmacokinetic model to predict breakthrough bleeding risk with ethinylestradiol (EE) combined oral contraceptives (COCs). The model accurately predicts EE levels, aiding in managing contraceptive efficacy and side effects during drug interactions.

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.7K
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

88.1K

Related Experiment Videos

Last Updated: Feb 12, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.6K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.7K
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

88.1K

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Contraception

Background:

  • Current combined oral contraceptives (COCs) use low-dose ethinylestradiol (EE) (≤35 μg) to mitigate cardiovascular disease (CVD) risks.
  • Lower EE doses increase breakthrough bleeding and contraceptive failure, especially with cytochrome P450 (CYP) enzyme inducers.
  • Understanding EE pharmacokinetics is crucial for optimizing COC safety and efficacy.

Purpose of the Study:

  • To develop and validate a physiologically based pharmacokinetic (PBPK) model for EE.
  • To quantitatively predict the impact of CYP3A4 inhibition and induction on EE pharmacokinetics.
  • To assess the risk of breakthrough bleeding associated with different EE doses and CYP modulation.

Main Methods:

  • Development of a PBPK model for EE pharmacokinetics.
  • Validation of the model using data from coadministration studies with CYP inhibitors (voriconazole, fluconazole) and inducers (rifampicin, carbamazepine).
  • Simulation of EE pharmacokinetics at various doses (20, 35, 50 μg) under different CYP modulation scenarios.

Main Results:

  • The PBPK model accurately predicted EE Cmax and AUC ratios (within 1.25 of observed data) during coadministration with key CYP modulators.
  • A threshold of 1,000 pg/ml.h for AUCss was established for breakthrough bleeding risk based on clinical data.
  • Simulations identified population percentages at risk of breakthrough bleeding for different EE doses and CYP modulation levels.

Conclusions:

  • The developed PBPK model provides a reliable tool for predicting EE pharmacokinetics and associated breakthrough bleeding risks.
  • This model can aid in personalized COC therapy, especially for patients on medications affecting CYP enzymes.
  • The findings support optimizing EE dosing strategies to minimize breakthrough bleeding and maintain contraceptive efficacy.